ENABLE Multiple Sclerosis (MS) Clinical Study
Austin Regional Clinic physicians constantly work to improve the care given to all our patients. We are dedicated to offering unique options for our patients and helping them reach their ideal health goals. Part of this dedication involves making clinical research available. Clinical research makes it possible to discover the benefits, risks, and safety of commercially available and investigational medications.
Research standards are very strict to help make studies as safe as possible. Teams of government and research experts have already reviewed each study we conduct to minimize any study risks. Austin Regional Clinic has decided to be involved in this research study because we believe it can potentially benefit our patients.
About the ENABLE clinical study
ENABLE is a long-term observational registry study to collect real-world data on BRIUMVI efficacy, safety, and tolerability in patients with multiple sclerosis (MS).
By participating in this study, you would be contributing to the development of groundbreaking technology with the potential to benefit many people in the future. ARC is one of the many study centers in the United States participating in this research study.
What to expect
We are currently seeking candidates for a clinical research study. During the study, patients can expect:
- A 96-week study with 6 infusions of BRIUMVI
- Site staff to collect data at each visit
- To complete questionnaires at each visit
Eligibility criteria
All participants must:
- Be at least 18 years old; adult patients with relapsing forms of MS
- Have a confirmed MS diagnosis
- Have been prescribed BRIUMVI but have not received their first infusion
- Have not received BRIUMVI infusion prior to enrollment
Location
Request to participate
Please contact our ARC Clinical Research team to request to participate by calling 737-247-7240.